---
figid: PMC4571765__z9k0141532820003
figlink: /pmc/articles/PMC4571765/figure/F3/
number: Fig. 3
caption: Working model of convergent pLTF pathways. The Q pathway to phrenic motor
  facilitation (pMF) is initiated by episodic activation of Gq protein-coupled 5-HT2
  receptors (; ) followed by PKCθ activation (), new brain-derived neurotrophic factor
  (BDNF) synthesis (), TrkB (; Dale EA and Mitchell GS, unpublished observations),
  and ERK/MAP kinase activation (Hoffman et al. 2012). The mechanism whereby ERK elicits
  pLTF remains unknown. We propose a newly organized “S” pathway (right) to pLTF initiated
  by adenosine 2A (A2A) receptors (), followed by cAMP production, EPAC, Akt, and
  mTOR activation () and new synthesis of immature TrkB isoforms (). Mechanisms downstream
  of iTrkB are unknown. S-to-Q pathway inhibition via PKA (Hoffman and Mitchell 2013)
  diverges at cAMP based on recent observations ().
pmcid: PMC4571765
papertitle: Mammalian target of rapamycin is required for phrenic long-term facilitation
  following severe but not moderate acute intermittent hypoxia.
reftext: Brendan J. Dougherty, et al. J Neurophysiol. 2015 Sep;114(3):1784-1791.
pmc_ranked_result_index: '82474'
pathway_score: 0.9742616
filename: z9k0141532820003.jpg
figtitle: Working model of convergent pLTF pathways
year: '2015'
organisms: Homo sapiens
ndex: da600808-dea8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4571765__z9k0141532820003.html
  '@type': Dataset
  description: Working model of convergent pLTF pathways. The Q pathway to phrenic
    motor facilitation (pMF) is initiated by episodic activation of Gq protein-coupled
    5-HT2 receptors (; ) followed by PKCθ activation (), new brain-derived neurotrophic
    factor (BDNF) synthesis (), TrkB (; Dale EA and Mitchell GS, unpublished observations),
    and ERK/MAP kinase activation (Hoffman et al. 2012). The mechanism whereby ERK
    elicits pLTF remains unknown. We propose a newly organized “S” pathway (right)
    to pLTF initiated by adenosine 2A (A2A) receptors (), followed by cAMP production,
    EPAC, Akt, and mTOR activation () and new synthesis of immature TrkB isoforms
    (). Mechanisms downstream of iTrkB are unknown. S-to-Q pathway inhibition via
    PKA (Hoffman and Mitchell 2013) diverges at cAMP based on recent observations
    ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRKCD
  - PRKCA
  - RAPGEF3
  - PRKD3
  - MAPK1
  - BDNF
  - PRKCE
  - PRKCB
  - PRKCH
  - MAPK3
  - PRKCQ
  - PRKCG
  - AKT1
  - AKT2
  - PRKACA
  - PRKCZ
  - GNAL
  - MTOR
  - PRKCI
  - GNAS
  - PRKAR1A
  - AKT3
  - HTR7
  - PRKACG
  - PRKAR2B
  - PRKACB
  - PRKAR2A
  - RPTOR
  - PRKAR1B
  - 5-HT
  - Glutamate
  - Cancer
genes:
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: EPAC
  symbol: EPAC
  source: hgnc_alias_symbol
  hgnc_symbol: RAPGEF3
  entrez: '10411'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BDNF
  symbol: BDNF
  source: hgnc_symbol
  hgnc_symbol: BDNF
  entrez: '627'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: Gs
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAL
  entrez: '2774'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: Gs
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAS
  entrez: '2778'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: 5-HT7
  symbol: 5-HT7
  source: hgnc_alias_symbol
  hgnc_symbol: HTR7
  entrez: '3363'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
chemicals:
- word: 5-HT
  source: MESH
  identifier: D012701
- word: Glutamate
  source: MESH
  identifier: D018698
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
